

1 **Title Page:**

2  
3

4 Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot  
5 Samples to Measure SARS-CoV-2 Humoral Immunogenicity

6

7 Aidan M. Nikiforuk (MSc)<sup>1,2</sup>, Brynn McMillan (MSc)<sup>1,4</sup>, Sofia R. Bartlett (PhD)<sup>1</sup>, Ana Citlali  
8 Márquez (PhD)<sup>1</sup>, Tamara Pidduck (Dipl T)<sup>1</sup>, Jesse Kustra (BSc)<sup>1</sup>, David M. Goldfarb (MD)<sup>3,5</sup>,  
9 Vilte Barakauskas (PhD, DABCC, FCACB)<sup>3,5</sup>, Graham Sinclair (PhD, FCCMG)<sup>3,5</sup>, David M.  
10 Patrick (MD)<sup>1,2</sup>, Manish Sadarangani (BM, BCh, DPhil)<sup>6,8</sup>, Gina S. Ogilvie (DrPH)<sup>2,7</sup>,  
11 Muhammad Morshed (PhD)<sup>1,3</sup>, Inna Sekirov (MD, PhD)<sup>1,3</sup>, Agatha N. Jassem (PhD)<sup>1,3</sup>.

12

13 **Word Count:** [1576]

14

15 **Affiliations:**

16 <sup>1</sup> British Columbia Centre for Disease Control, Vancouver, BC, V5Z 4R4, Canada

17

18 <sup>2</sup> School of Population and Public Health, University of British Columbia, Vancouver, BC, V6T  
19 1Z4, Canada

20

21 <sup>3</sup> Department of Pathology and Laboratory Medicine, University of British Columbia,  
22 Vancouver, BC, V6T 1Z4, Canada

23

24 <sup>4</sup> Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V5Z  
25 1M9, Canada

26

27 <sup>5</sup> Department of Pathology and Laboratory Medicine, British Columbia Children's and Women's  
28 Hospital, Vancouver, BC, V6H 3V4, Canada

29

30 <sup>6</sup> Vaccine Evaluation Center, British Columbia Children's Hospital Research Institute,  
31 Vancouver, BC, V5Z 4H4, Canada

32

33 <sup>7</sup> Women's Health Research Institute, Vancouver, BC, V6H 2N9, Canada

34

35 <sup>8</sup> Department of Pediatrics, British Columbia Children's Hospital, Vancouver, BC, V6H 3V4,  
36 Canada

37

38 **Corresponding Author:** Agatha N. Jassem (PhD), Clinical Microbiologist-Virology, British

39 Columbia Centre for Disease Control (BCCDC), BC V5Z 4R4, Canada, email:

40 [Agatha.Jassem@bccdc.ca](mailto:Agatha.Jassem@bccdc.ca), phone: (604) 707-2625.

41 **Key Points:**

42

43 Question: What is the diagnostic accuracy and predictive value of immunoglobulin G serology  
44 on finger prick capillary dried blood spot samples to measure SARS-CoV-2 humoral  
45 immunogenicity?

46

47 Findings: In comparison to a paired-serum reference, dried blood spot samples tested for anti-  
48 SARS-CoV-2 IgG possess a sensitivity of 80% (95% CI: 61%-91%) and specificity of 97%  
49 (95% CI: 95%-98%). Dried blood spot testing has a positive predictive value of 98% (95% CI:  
50 98%-99%) when modelled in a theoretical population with COVID-19 vaccine coverage of  
51 seventy-five percent.

52

53 Meaning: Dried blood spot samples have equal diagnostic accuracy to serum collected by  
54 venipuncture when tested by electrochemiluminescence assay and should be considered to  
55 reliably detect SARS-CoV-2 seropositivity.

56

57

58

59

60

61

62

63 **Abstract:**

64 Importance: Measuring humoral immunogenicity of Severe Acute Respiratory Syndrome  
65 Coronavirus 2 vaccines and finding population-level correlates of protection against coronavirus  
66 disease presents an immediate challenge to public health practitioners.

67 Objective: To study the diagnostic accuracy and predictive value of finger prick capillary dried  
68 blood spot samples tested using an anti-immunoglobulin G (IgG) serology assay to measure  
69 SARS-CoV-2 seropositivity and the humoral immunogenicity of COVID-19 vaccination.

70 Design, Setting and Participants: This cross-sectional study enrolled participants (n= 644) who  
71 had paired DBS and serum samples collected by finger prick and venipuncture, respectively, in  
72 British Columbia, Canada between January 12<sup>th</sup>, 2020 and May 21<sup>st</sup>, 2021. Samples were tested  
73 by a multiplex electrochemiluminescence assay for SARS-CoV-2 anti-Spike (S), -Nucleocapsid  
74 (N) and -receptor binding domain (RBD) IgG reactivity using a Meso Scale Discovery (MSD)  
75 platform. Additionally, unpaired DBS samples (n= 6,706) that were collected in the province  
76 during the same time period were included for analysis of SARS-CoV-2 anti-N IgG reactivity.

77 Exposure: Collection of a capillary dried blood spot by finger prick alone or paired with serum  
78 by venipuncture.

79 Outcome: Humoral immune response to SARS-CoV-2 measured by detection of anti-S, -N or -  
80 RBD IgG.

81 Results: In comparison to a paired-serum reference, dried blood spot samples possess a  
82 sensitivity of 80% (95% CI: 61%-91%) and specificity of 97% (95% CI: 95%-98%). Receiver  
83 operator characteristic curve analysis (ROC) found that participant DBS samples tested for anti-  
84 SARS-CoV-2 IgG by MSD V-PLEX COVID-19 Coronavirus Panel 2 assay accurately classify  
85 SARS-CoV-2 seroconversion at an 88% percent rate, AUC= 88% (95% CI: 81%-96%).

86 Modelling found that a dried blood spot-based testing approach has a high positive predictive  
87 value (98% [95% CI: 98%-99%]) in a theoretical population with seventy-five percent COVID-  
88 19 vaccine coverage. At lower vaccine coverages of fifteen and forty-five percent, the test's  
89 positive predictive value decreased, and the negative predictive value increased.

90 Conclusion: We demonstrate that dried blood spot collected samples, when tested using an  
91 electrochemiluminescence assay, provide a valid alternative to traditional venipuncture and  
92 should be considered to reliably detect SARS-CoV-2 seropositivity.

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109 **Introduction:**

110 The ongoing global vaccination campaign to immunize populations against Severe Acute  
111 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus  
112 disease (COVID-19), represents the largest primary prevention effort undertaken in public health  
113 since the Global Polio Eradication Initiative (GPEI)<sup>1</sup>. Lessons learned from the GPEI highlight  
114 the value of measuring population level vaccine elicited immunogenicity, as the humoral  
115 response can differ between doses, age groups, vaccine formulations and viral strains<sup>1</sup>.

116 The size and scale of the COVID-19 vaccination campaign raises logistical challenges in  
117 measuring the humoral immunogenicity of SARS-CoV-2 vaccination at the population level. The  
118 requirement for high volume serologic testing to detect vaccine elicited immunogenicity  
119 represents a particular challenge, as whole blood specimen collection by venipuncture does not  
120 easily scale up<sup>2,3</sup>. Whole blood collection in the form of serum or plasma requires a trained  
121 phlebotomist, specific collection tubes, and cold chain logistics. Dried blood spot (DBS)  
122 sampling is a cost effective and promising alternative, which can occur by self-collection,  
123 eliminating the need for trained personnel. Collection cards are stable at ambient temperatures  
124 for up to two weeks, simplifying transport, and can be stored in large quantities using less space<sup>4</sup>.  
125 To understand the potential of DBS samples in measuring SARS-CoV-2 seropositivity at the  
126 population level we: i) evaluated the diagnostic accuracy of DBS tested by Meso Scale  
127 Discovery (DBS-MSD) multiplex anti-IgG electrochemiluminescence assay in comparison to a  
128 paired-serum reference in study participants (n= 644; 30 positive and 614 negative) from British  
129 Columbia, Canada and, ii) modelled the predictive performance of DBS-MSD testing in a  
130 theoretical population (n=10,000) with stratified COVID-19 vaccine coverage of fifteen, forty-  
131 five and seventy-five percent.

132 **Methods:**

133 Paired participant samples (n= 644) were received at the British Columbia Centre for  
134 Disease Control Public Health Laboratory. Serum samples were collected from venipuncture by  
135 trained phlebotomists in 5ml tubes (BD Vacutainer® SST™ Tubes: #367986), centrifuged and  
136 tested before storage at -20°C. DBS samples were collected by capillary finger-prick using a  
137 contact activated lancet (BD Microtainer®: #366594), spotted on protein saver cards (Whatman  
138 903™: #Z761575), sealed in a gas-impermeable sachet with 1gm of desiccant per card, and stored  
139 at -20°C. DBS sample collection was performed by a health care worker or by self-collection.  
140 Written instructions were provided to participants who were asked to self-collect. Four 6mm  
141 punches were eluted in dipotassium phosphate buffered saline with 0.5% sodium azide and 1.5%  
142 bovine serum albumin w/v (Ortho Clinical Diagnostics, personal communication). Serum  
143 samples were diluted 1:5000 v/v and DBS samples were diluted 1:500 v/v in Diluent 100 (MSD:  
144 #R50AA-2) before serological testing. Serological testing was performed with the V-PLEX  
145 COVID-19 Coronavirus Panel 2 (IgG) (MSD: #K15369U), offered by MSD<sup>5</sup>. Reference  
146 positive samples were defined as the paired serum samples that had signals above the MSD  
147 recommended target thresholds for anti-Spike (S), and/or -Nucleocapsid (N) and/or -receptor  
148 binding domain (RBD) IgG (S=1960, N=5000 and RBD=538)<sup>5</sup>. Serum samples were classified  
149 as positive for SARS-CoV-2 anti-IgG when signal for two of three targets was greater-than or  
150 equal-to the threshold. Thresholds were set for DBS-MSD results by plotting distributions of  
151 anti-S and -N IgG signals. DBS-MSD samples were classified as positive if the anti-S and -N  
152 signal or only the anti-S signal was greater-than or equal-to the thresholds established for DBS  
153 samples. Nucleocapsid-only positive DBS-MSD samples were classified as negative. Anti-RBD  
154 results were not interpreted for DBS samples, as they were found to be highly correlated with

155 anti-S signals (Pearson's correlation,  $r = 95\%$ , 95% CI [92%-97%]), indicating collinearity<sup>6</sup>.  
156 Sensitivity and specificity of DBS-MSD was calculated in comparison to the paired-serum  
157 reference. Logistic regression was used to predict the paired-serum reference diagnosis by DBS-  
158 MSD result<sup>7</sup>. Internal cross-validation was performed by a  $n = 2,000$  bootstrap and results were  
159 plotted as a receiver operator characteristic curve (ROC)<sup>8,9</sup>. The positive- and negative-  
160 predictive value (PPV, NPV) of DBS-MSD was modelled in a theoretical population of ten-  
161 thousand persons ( $n = 10,000$ ) with varying COVID-19 vaccine coverage of fifteen, forty-five  
162 and seventy-five percent<sup>10,11</sup>.

163

164 The University of British Columbia Clinical Research Ethics Board provided ethical  
165 review and approval for studies from which participants' specimens were cross-sectionally  
166 sampled and tested (H20-02184, H20-02402, H20-01421 and H20-01886).

167

168

169

170

171

172

173

174

175

176

177 **Results:**

178 Signal target thresholds for DBS-MSD were established at 75 AU/ml (95% CI: 55-95  
179 AU/ml) for anti-S (Figure 1a) and 175 AU/ml (95% CI: 162-188 AU/ml) anti-N IgG (Figure 1b),  
180 based on the observed distribution of signals in DBS samples. The anti-S and anti-N thresholds  
181 were set to maximize sensitivity and specificity, respectively. The anti-S distribution shows that  
182 77% of SARS-CoV-2 serum positive samples have a DBS signal greater than or equal to the  
183 threshold (one sample T-test,  $P=0.77$ , Sensitivity= 77%). The anti-N distribution estimates that  
184 95% of anti-S negative DBS samples have a signal less than or equal to the threshold (one  
185 sample T-test,  $P=0.05$ , Specificity= 95%). Applying these thresholds to the same dataset ( $n=$   
186 644), DBS-MSD achieved a sensitivity of 80% (95% CI: 61%-91%) and specificity of 97%  
187 (95% CI: 95%-98%) in comparison to the paired-serum reference (Figure 2a). Internally cross-  
188 validated ROC analysis yielded an area under the curve of 88% (95% CI: 81%-96%) (Figure 2b).  
189 DBS samples resulted on MSD will accurately classify SARS-CoV-2 seroconversion at an 88%  
190 percent rate. In a theoretical population of 10,000 persons, of which seventy-five percent have  
191 received COVID-19 immunization, a positive test result predicts true seropositivity at a 98%  
192 rate, PPV= 98% (95% CI: 98%-99%) (Figure 3). A negative test result predicts a seronegative  
193 response at a 38% rate, NPV= 38% (95% CI: 37%-40%). At lower vaccine coverages of fifteen  
194 and forty-five percent, the PPV of DBS-MSD decreased and the NPV increased ( $PPV_{15} = 29%$   
195 (95% CI: 25%-33%),  $NPV_{15} = 99%$  (95% CI: 99%-100%) and  $PPV_{45} = 96%$  (95% CI: 95%-  
196 96%),  $NPV_{45} = 86%$  (95% CI: 85%-86%). |

197

198

199



200 **Discussion:**

201           The diagnostic accuracy of DBS-MSD is comparable to that of the Roche Elecsys<sup>®</sup>  
202 platform for surveillance of SARS-CoV-2 seroconversion<sup>12</sup>. Tests performed on DBS samples  
203 characteristically exhibit high specificity and low sensitivity, attributable to low analyte  
204 concentration, variance in sample collection practices or time since antigen exposure<sup>13</sup>. We show  
205 that, despite the expected disadvantage of low analyte concentration, DBS-MSD testing may  
206 possess a strong PPV when implemented in a context with high SARS-CoV-2 seroprevalence  
207 (e.g., post a successful COVID-19 immunization campaign). Therefore, DBS collection and anti-  
208 IgG serology shows promise as a tool to measure SARS-CoV-2 seropositivity at the population  
209 level. The benefits include comparable diagnostic accuracy to that of serum samples, with  
210 improved population reach, and the potential to discriminate natural from vaccine elicited  
211 seroconversion by measuring anti-S and anti-N IgG reactivity<sup>14</sup>. In a theoretical population with  
212 seventy-five percent COVID-19 vaccine coverage, a positive DBS-MSD result reliably indicates  
213 seropositivity with a high PPV and does not require additional testing. The low NPV indicates  
214 that a negative result does not reliably predict lack of an immune response or immunosenescence  
215 and may require reflex testing. In receipt of a negative result, where confirmation of individual  
216 serostatus is required, reflex testing may entail additional testing from venipuncture or DBS.

217           An important limitation of SARS-CoV-2 seroprevalence studies in populations with low  
218 vaccine coverage is the difference in antibody signals between individuals who have recovered  
219 from asymptomatic and symptomatic infection<sup>15</sup>. The distribution of serological signals between  
220 recovered asymptomatic and negative cases are more likely to overlap than when comparing  
221 negative to recovered symptomatic, nucleic acid amplification test confirmed cases. Low  
222 serological signal should not be a limitation in populations with high vaccine coverage, as

223 SARS-CoV-2 vaccination has been experimentally found to elicit a stronger humoral immune  
224 response than natural infection<sup>16</sup>.

225 In summary, measuring SARS-CoV-2 seropositivity at the population level presents  
226 unique challenges, which warrant investigation and consideration of alternative methodologies.  
227 We show robust diagnostic accuracy of DBS samples when tested for anti-SARS-CoV-2 IgG  
228 using an MSD assay, and model the predictive value of DBS-MSD testing in a theoretical  
229 population with fifteen, forty-five and seventy-five percent COVID-19 vaccine coverage<sup>11</sup>. DBS  
230 tests have comparable specificity and lower sensitivity to those conducted on serum, due to low  
231 analyte volume and the need for additional sample processing. The PPV of DBS-MSD testing  
232 increases in response to high seroprevalence, making it possible to accurately identify  
233 individuals who have a humoral immune response. Follow-up, reflex testing may be required to  
234 confirm true negatives. The sensitivity and NPV of DBS-MSD testing will likely increase in an  
235 immunized population, as vaccinated individuals have a more robust humoral response than  
236 those that are naturally infected<sup>16</sup>.

237 At the population level, naturally infected and vaccinated individuals can be considered a  
238 homogenized group, where an anti-S IgG positive signal indicates seroreactivity. Conversely,  
239 individual diagnosis may require further interpretation where anti-S IgG positive persons are  
240 further stratified by their anti-N IgG results and/or clinical information (e.g., vaccination status,  
241 prior laboratory results) to determine natural infection from vaccine elicited immunity. Detection  
242 of natural infection by serology alone is dependent on study design, as anti-N IgG signal may  
243 wane when the time between exposure and sample collection lengthens.

244 Public health practitioners should consider the utility of DBS-MSD to evaluate SARS-  
245 CoV-2 seropositivity from natural infection or COVID-19 vaccination. Modelling shows this

246 combination possesses a strong PPV (~ 98%) in settings of high seroprevalence (e.g., seventy-  
247 five percent COVID-19 vaccine coverage). Public health agencies are challenged with  
248 simultaneously administering COVID-19 vaccines and measuring the elicited immune response.  
249 To address the later, a reliable and accessible method for detecting SARS-CoV-2 seropositivity  
250 is required. The logistic, economic and demonstrated diagnostic accuracy of DBS-MSD make it  
251 a strong candidate for population level investigation of SARS-CoV-2 humoral immunogenicity,  
252 especially in longitudinal study designs requiring repeated measures.

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269 **Acknowledgements:**

270           This study was funded by the Michael Smith Foundation for Health Research (COV-  
271 2020-1120, COV-2020-1279) and Genome British Columbia (COV-050). Additional funding  
272 was provided by the Public Health Agency of Canada through the COVID-19 Immunity  
273 Taskforce (2021-HQ-000141), BC SUPPORT Unit (C19-PE-V4), Canadian Institutes of Health  
274 Research (#434951) and the University of British Columbia-Public Scholars Initiative. M.S. is  
275 supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child  
276 Health Clinician Scientist Program and the Michael Smith Foundation for Health Research.

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292 **Contributions:**

293 A.M.N. contributed to attaining funding, performed serological testing, data analysis, wrote and  
294 edited the manuscript.

295 B.M. assisted with sample acquisition, planning, performed serological testing, acquiring and  
296 interpreting data. B.M. assisted in writing and editing the manuscript.

297 S.R.B. contributed to attaining funding, designing the study, sample collection, serological  
298 testing. S.B. discussed the results of the data analysis and assisted in interpreting the results.

299 A.C.M. assisted in planning experiments, data analysis and interpretation of the results.

300 T.P. and J.K. assisted with sample acquisition, planning and performing experiments, and  
301 acquiring data.

302 G.D. and V.B. assisted in collecting paired samples from participants at the CW campus and  
303 evaluation of validation data.

304 G.S. and V.B. assisted with study design related to DBS collection and testing.

305 D.M.P. assisted in data interpretation and edited the manuscript.

306 M.S., G.S.O., M.M., I.S. contributed to the study design, data interpretation and edited the  
307 manuscript.

308 A.N.J. obtained grant funding, contributed to the study design and assisted in interpreting the  
309 results, writing and editing the manuscript.

310

311

312

313

314 **Conflict of Interest Disclosures:**

315           S.R.B. has advised and spoken for Gilead Sciences and AbbVie (all personal payments  
316 given as unrestricted donations to BC Centre for Disease Control Foundation for Public Health)  
317 and has received investigator-initiated research funding from Gilead Sciences via her institution.  
318 M.S. has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-  
319 Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he  
320 has not received any personal payments.

321

322 **References [16]:**

323

324 1. Voorman A, Hoff NA, Doshi RH, et al. Polio immunity and the impact of mass  
325 immunization campaigns in the Democratic Republic of the Congo. *Vaccine*.  
326 2017;35(42):5693-5699. doi:10.1016/j.vaccine.2017.08.063

327 2. Parker SP, Cubitt WD. The use of the dried blood spot sample in epidemiological studies.  
328 *J Clin Pathol*. 1999;52(9):633-639. doi:10.1136/jcp.52.9.633

329 3. Lei BUW, Prow TW. A review of microsampling techniques and their social impact.  
330 *Biomed Microdevices*. 2019;21(4):81. doi:10.1007/s10544-019-0412-y

331 4. Malsagova K, Kopylov A, Stepanov A, Butkova T, Izotov A, Kaysheva A. Dried Blood  
332 Spot in Laboratory: Directions and Prospects. *Diagnostics*. 2020;10(4):248.  
333 doi:10.3390/diagnostics10040248

334 5. Meso Scale Discovery. V-PLEX COVID-19 Coronavirus Panel 2 (IgG) Kit. Published  
335 2021. <https://www.mesoscale.com/products/covid-19-coronavirus-panel-2-igg-k15369u/>

336 6. García CB, García J, López Martín MM, Salmerón R. Collinearity: revisiting the variance  
337 inflation factor in ridge regression. *J Appl Stat*. 2015;42(3):648-661.  
338 doi:10.1080/02664763.2014.980789

339 7. Lever J, Krzywinski M, Altman N. Logistic regression. *Nat Methods*. 2016;13(7):541-542.  
340 doi:10.1038/nmeth.3904

341 8. Hesterberg T. Bootstrap. *Wiley Interdiscip Rev Comput Stat*. 2011;3(6):497-526.  
342 doi:10.1002/wics.182


343 9. Grzybowski M, Younger JG. Statistical Methodology: III. Receiver Operating  
344 Characteristic (ROC) Curves. *Acad Emerg Med*. 1997;4(8):818-826. doi:10.1111/j.1553-

- 345 2712.1997.tb03793.x
- 346 10. Public Health Agency of Canada. *COVID-19: Life after Vaccination.*; 2021.
- 347 [https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/awareness-resources/vaccinated-against-covid-19.html)
- 348 [infection/awareness-resources/vaccinated-against-covid-19.html](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/awareness-resources/vaccinated-against-covid-19.html)
- 349 11. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity
- 350 to SARS-CoV-2 infection by mass vaccination. *Lancet*. 2020;396(10263):1614-1616.
- 351 doi:10.1016/S0140-6736(20)32318-7
- 352 12. Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-
- 353 CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay. *J*
- 354 *Clin Virol*. 2021;136:104739. doi:10.1016/j.jcv.2021.104739
- 355 13. Stefic K, Guinard J, Peytavin G, et al. Screening for Human Immunodeficiency Virus
- 356 Infection by Use of a Fourth-Generation Antigen/Antibody Assay and Dried Blood Spots:
- 357 In-Depth Analysis of Sensitivity and Performance Assessment in a Cross-Sectional Study.
- 358 Caliendo AM, ed. *J Clin Microbiol*. 2019;58(1). doi:10.1128/JCM.01645-19
- 359 14. Demmer RT, Baumgartner B, Wiggen TD, et al. Identification of natural SARS-CoV-2
- 360 infection in seroprevalence studies among vaccinated populations. *medRxiv Prepr Serv*
- 361 *Heal Sci*. Published online April 19, 2021. doi:10.1101/2021.04.12.21255330
- 362 15. Jiang C, Wang Y, Hu M, et al. Antibody seroconversion in asymptomatic and
- 363 symptomatic patients infected with severe acute respiratory syndrome coronavirus 2
- 364 (SARS-CoV-2). *Clin Transl Immunol*. 2020;9(9). doi:10.1002/cti2.1182
- 365 16. Widge AT, Roupael NG, Jackson LA, et al. Durability of Responses after SARS-CoV-2
- 366 mRNA-1273 Vaccination. *N Engl J Med*. 2021;384(1):80-82.
- 367 doi:10.1056/NEJMc2032195
- 368



369

## Figures:



370

371 **Figure 1:** Signal distributions of SARS-CoV-2 anti-Spike (S) and -Nucleocapsid (N) IgG collected by DBS and tested with an MSD assay. **a)**

372 Participant DBS and paired-serum samples n=644, were tested by MSD assay for anti-S, -N and -receptor binding domain (RBD) IgG. DBS-

373 MSD anti-S signals were stratified by MSD test-results on paired-serum samples (white: paired-serum positive) (grey: paired-serum negative). A

374 sample was classified as paired-serum positive when greater-than or equal-to two of three target signals exceeded the manufacturer recommended

375 thresholds (S= 1960, N= 5000 and RBD= 538). A threshold of  $\geq 75$  AU/ml (95% CI: 55-95 AU/ml) was set for anti-S DBS samples tested on


376 MSD, as it discriminates paired-serum positives from negatives. In a random sample of serum positives, 77% of paired-DBS-MSD samples are

377 expected to have values greater than or equal to 75 AU/ml (one sample T-test,  $P= 0.77$ , Sensitivity= 77%). **b)** All anti-N DBS-MSD samples

378 tested at the BCCDC to May 21<sup>st</sup>, 2021 were restricted to those with DBS-MSD anti-S < 75 AU/ml (n= 6,706) (dark grey). A threshold of  $\geq 175$

379 AU/ml (95% CI: 162-188 AU/ml) was set for anti-N DBS samples tested on MSD, as the probability of classifying an anti-S negative DBS-MSD  
380 sample anti-N positive equals 5% (one sample T-test, P= 0.05, Specificity= 95%). DBS-MSD samples were classified positive if anti-S signal  
381 was  $\geq 75$  AU/ml and anti-N signal was  $\geq 175$  AU/ml or anti-S signal was  $\geq 75$  AU/ml and anti-N signal was  $< 175$  AU/ml. Samples with anti-S  
382 signal  $< 75$  AU/ml and anti-N signal  $\geq 175$  AU/ml were classified as negative.

383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404



405

406 **Figure 2:** Confusion matrix and internally cross-validated receiver operating characteristic curve analysis of DBS-MSD test result in comparison

407 to the paired-serum reference. **a)** Frequency of DBS-MSD results are reported in comparison to the reference and used to calculate clinical

408 accuracy (sensitivity and specificity). In comparison to the paired-serum reference, DBS-MSD possesses a sensitivity of 80% (95% CI: 61%-

409 91%) and specificity of 97% (95% CI: 95%-98%), grey area shows the proportion of participants by cell and black lines represent the 95%

410 confidence interval. No evidence of similarity between the marginal outcome probability was observed (McNemar test,  $P < 0.007$ ).

411 **b)** Internally cross-validated receiver operator characteristic curve analysis was used to quantify the predictive ability of a DBS-MSD test in comparison to the

412 reference. DBS-MSD was found to accurately discriminate natural SARS-CoV-2 seroconversion at an 88% (95% CI: 81%-96%) rate (bootstrap=

413 2000).

414

415

416


417

418

419

420

421



422

423

424

425

426

427

428

429

430

**Figure 3:** Confusion matrix showing the predictive performance of MSD-DBS in a theoretical population (n=10,000) with seventy-five percent SARS-CoV-2 vaccine coverage. The positive-predictive value (PPV) of MSD-DBS is positively correlated with the prevalence of SARS-CoV-2 seroreactivity. At seventy-five percent SARS-CoV-2 vaccine coverage, a positive MSD-DBS test would correctly identify vaccine elicited seroreactivity at a 98% rate, PPV= 98% (95% CI: 98%-99%). A negative MSD-DBS test correctly identifies no vaccine elicited seroreactivity at a 38% rate, negative predictive value (NPV)= 38% (95% CI: 37%-40%). There was no evidence of independence between results (Chi<sup>2</sup> test, P<0.001).